Edition:
India

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

50.90NOK
18 May 2018
Change (% chg)

kr2.04 (+4.18%)
Prev Close
kr48.86
Open
kr48.86
Day's High
kr51.50
Day's Low
kr48.40
Volume
207,832
Avg. Vol
370,150
52-wk High
kr113.00
52-wk Low
kr37.26

Chart for

About

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide... (more)

Overall

Beta: --
Market Cap(Mil.): kr4,031.45
Shares Outstanding(Mil.): 49.04
Dividend: --
Yield (%): --

Financials

BRIEF-Nordic Nanovector Appoints Tone Kvåle As Interim Chief Executive Officer

* NORDIC NANOVECTOR APPOINTS TONE KVÅLE AS INTERIM CHIEF EXECUTIVE OFFICER

20 Apr 2018

BRIEF-Nordic Nanovector Says Humalutin Has Shown Significant Tumour Uptake

* POSTER REPORTING ANTI -TUMOUR EFFECT OF HUMALUTIN® (177LU-CONJUGATED HUMANIZED ANTI-CD37 ANTIBODY, 177LU-NNV003) IN PRECLINICAL MODELS OF NON-HODGKIN'S LYMPHOMA (NHL) WAS PRESENTED YESTERDAY

16 Apr 2018

BRIEF-Nordic Nanovector's ex-CEO bought 10,000 shares

* ‍LUIGI COSTA, WHO RESIGNED AS CEO ON WEDNESDAY, HAS ON APRIL 5 PURCHASED 10,000 SHARES IN NORDIC NANOVECTOR ASA AT AN AVERAGE SHARE PRICE OF NOK 43.56​

05 Apr 2018

Nordic Nanovector hopes to have CEO replacement shortly

April 5 Nordic Nanovector ASA Chairman Ludvik Sandnes told reporters and analysts on Thursday:

05 Apr 2018

BRIEF-Nordic Nanovector's Paradigme faces delay, Humalutin indefinitely postponed

* ‍NORDIC NANOVECTOR PROVIDES UPDATE ON PARADIGME CLINICAL TRIAL​

05 Apr 2018

BRIEF-‍Nordic Nanovector Says Luigi Costa Will Step Down As CEO

* ‍NORDIC NANOVECTOR ANNOUNCES THAT LUIGI COSTA WILL STEP DOWN AS CHIEF EXECUTIVE OFFICER​

05 Apr 2018

BRIEF-Nordic Nanovector Q4 Comprehensive Loss At NOK ‍87.6​ Mln

* Q4 COMPREHENSIVE LOSS NOK ‍87.6​ MILLION VERSUS LOSS NOK 59.3 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

27 Feb 2018

BRIEF-Nordic Nanovector presents updated results

* BETALUTIN® SHOWS STRONG CLINICAL PROFILE IN RELAPSED/REFRACTORY INDOLENT NHL AND FOLLICULAR LYMPHOMA

11 Dec 2017

BRIEF-Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​

* ‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​

22 Nov 2017

Earnings vs. Estimates